Drug Trial Radar · NCT06270316
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Dec 1, 2027
Study completion Nov 30, 2031
Sponsor
- Lead sponsor
- UniQure Biopharma B.V.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
Conditions
- Fabry Disease
Interventions
AMT-191Drug
A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of different dose levels of intravenously-administered AMT-191 in Participants with FDTime frame: 60 Months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The Kirklin Clinic Of University of Alabama Birmingham Hospital
Birmingham, Alabama · Recruiting
University of California Los Angeles (UCLA)
Los Angeles, California · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
MHealth Fairview University of Minnesota Medical Center East Bank
Minneapolis, Minnesota · Recruiting
NYC Health + Hospitals/Metropolitan
New York, New York · Recruiting
Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
University of Utah, Clinical and Translational Sciences Institute
Salt Lake City, Utah · Recruiting
Lysosomal & Rare Disorders Research and Treatment Center, Inc
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.